Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

Biotech firm Eikon Therapeutics raises $381M in an oversubscribed IPO. The cancer & neurology drugmaker is the third successful biotech offering of 2026.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm ...

Forgent, Eikon, and Bob’s Discount Furniture are making their debut in a mixed market for IPOs. SpaceX and other AI stocks ...

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.